Home › Funds › ADAR1 Capital Management, LLC › ELVN
ADAR1 Capital Management, LLC position in ELVN
ENLIVEN THERAPEUTICS INC · Health Care
ADAR1 Capital Management, LLC reported holding 442,682 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$20.3M, representing 1.11% of its reported portfolio and ranking #19 among its reported holdings. ADAR1 Capital Management, LLC has disclosed ELVN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How ADAR1 Capital Management, LLC's ELVN position evolved
ADAR1 Capital Management, LLC first disclosed a stake in ELVN in Q4 2025 at 30,000 shares (US$462K). The position peaked in Q3 2026 at 442,682 shares, worth US$20.3M. Across 4 filings, ADAR1 Capital Management, LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 442,682 shares valued at US$20.3M — an increase of 54,964 shares quarter over quarter.. Notable position changes include a 998% increase in Q1 2026 (shares rose 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 30.00K | $462.00K | New |
| Q1 2026 | 329.54K | $12.92M | Add |
| Q2 2026 | 387.72K | $19.68M | Add |
| Q3 2026 | 442.68K | $20.29M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ELVN and 13F data
ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 61 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$294.5M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ELVN
- ORBIMED ADVISORS LLC 6.78M sh · $343.91M · Q2 2026
- Polar Capital Holdings Plc 6.43M sh · $294.53M · Q3 2026
- Vestal Point Capital, LP 4.00M sh · $203.00M · Q2 2026
- Commodore Capital LP 3.27M sh · $166.21M · Q2 2026
- Fairmount Funds Management LLC 1.86M sh · $94.17M · Q2 2026
- Bellevue Group AG 1.49M sh · $75.62M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $69.06M · Q2 2026
- Siren, L.L.C. 1.48M sh · $67.62M · Q3 2026
- Novo Holdings A/S 1.00M sh · $50.75M · Q2 2026
- Logos Global Management LP 1.08M sh · $49.51M · Q3 2026
- BAKER BROS. ADVISORS LP 905.19K sh · $45.94M · Q2 2026
- First Turn Management, LLC 958.70K sh · $43.95M · Q3 2026
More on ADAR1 Capital Management, LLC
FAQ
How long has ADAR1 Capital Management, LLC held ELVN?
ADAR1 Capital Management, LLC has disclosed ELVN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is ADAR1 Capital Management, LLC's current position in ELVN?
As of Q3 2026, ADAR1 Capital Management, LLC holds 442.68K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $20.29M, representing 1.11% of its reported portfolio and ranking #19.
Has ADAR1 Capital Management, LLC been buying or selling ELVN?
In the latest 13F filing (Q3 2026), ADAR1 Capital Management, LLC increased its position in ELVN. The position peaked in Q3 2026 at 442.68K shares.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 61 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.